WHO targets on isolating patients and medical burials missed as NGO warns virus has reduced country to ‘a nation of mere beggars’

THE GUARDIAN   By  Lisa O'Carroll                                                                                           Dec. 1, 2014

FREETOWN --SIERRA Leone-- 
Ebola continues to surge in Sierra Leone, with the number of cases quintupling in Freetown alone in the past two months, according to new figures.

A health worker gives a drink to a young patient at the Kenema treatment centre, Sierra Leone. Photograph: Francisco Leong/AFP/Getty Images

BBC    By   Mark Doyle                                                                                                        Dec. 1, 2014

Tony Banbury declined to say if targets he had set in the fight against Ebola, to be achieved by Monday, had been met.

The targets were for the proportion of people being treated and for the safe burial of highly infectious bodies.

In October, Mr Banbury told the UN Security Council that by 1 December, "70% of all those infected by the disease must be under treatment and 70% of the victims safely buried if the outbreak is to be successfully arrested".

Mr Banbury said the 70% targets were being met in "the vast majority" of areas in the three worst-affected countries - Guinea, Sierra Leone and Liberia.

"But in some areas", he said, "including here in Sierra Leone - especially in the capital Freetown and in the town of Port Loko - we are falling short. And it is in those areas where we really need to focus our assets and our capabilities".

Read complete story

           

nejm.org

A collection of articles and other resources on the Ebola outbreak, including clinical reports, management guidelines, and commentary.

CLICK HERE - NEJM Ebola Outbreak page, where all content is FREE

https://www.facebook.com/TheNewEnglandJournalofMedicine/posts/10152498380218462

DESIGN & TREND  by Randall Mayes                                                                             Nov. 29, 2014

Over the last decade, we have witnessed the emergence of Superbugs, various strains of bird flu and now Ebola, which do not have geographical borders.

Consequently, there is a pressing need for international cooperation to control these pandemics.

In a new study, researchers have identified obstacles that are currently preventing the world from sharing health data, reports Science Daily.

While performing a literature search for the study, an international group of researchers discovered over 1,400 scientific articles related to sharing public health data. From those articles, they found two broad categories that need to be addressed.

Read comlete story
http://www.designntrend.com/articles/28008/20141129/urgent-need-improved-infrastructure-share-health-data.htm

Link to article  in Science Daily
http://www.sciencedaily.com/releases/2014/11/141125102102.htm

                              

wellcome.ac.uk - November 28, 2014

A rapid, point-of-care diagnostic test for the Ebola virus will be trialled in the coming weeks at the Ebola treatment centre in Conakry, Guinea. The trial is one of six health research projects that have been jointly funded by the Wellcome Trust and the UK government.

The 15-minute Ebola test is six times faster than similar tests currently in use and aims to speed up the diagnosis of Ebola cases. Early detection of Ebola leads to better infection control as medical staff can identify and isolate confirmed cases of Ebola faster, and start treating patients sooner. Ultimately, a faster test could reduce Ebola transmission and mortality.

The project is supported through a joint Department for International Development (DFID) and Wellcome Trust fund for rapid health research during the Ebola outbreak. The six projects are managed by Enhancing Learning & Research for Humanitarian Assistance (ELRHA).

REUTERS                                                                                                                      NOV. 28, 2014

LONDON --Men who recover from Ebola should abstain from sex for three months to minimize the risk of passing the virus on in their semen, the World Health Organization (WHO) said on Friday.

Ebola, a disease that has infected and killing thousands in a vast epidemic in West Africa, normally spreads via bodily fluids such as blood, saliva and faeces. Although sexual transmission of Ebola virus disease has never been documented, the virus has been detected in the survivors' semen.

"Men who have recovered from Ebola virus disease should be aware that seminal fluid may be infectious for as long as three months after onset of symptoms," the WHO said in a statement....

Read complete story
http://www.reuters.com/article/2014/11/28/us-health-ebola-sex-idUSKCN0JC0UP20141128

NEW YORK TIMES   By Jeffrey Gettleman                        Nov.28, 2014

KISSI TOWN, Sierra Leone-- ...While health officials say they are making headway against the Ebola epidemic in neighboring Liberia, the disease is still raging in Sierra Leone, despite the big international push. In November alone, the World Health Organization has reported more than 1,800 new cases in this country, about three times as many as in Liberia, which until recently had been the center of the outbreak....

On Freetown’s outskirts, burly youth are setting up roadblocks. The police are nowhere to be found. The young men barricade the road brandishing digital thermometers. Credit Daniel Berehulak for The New York Times

voanews.com - by Henry Ridgwell - Nov 28, 2014



Dozens of British music stars have come together to record a new version of the song ‘Do They Know It’s Christmas?’ to raise money for the fight against Ebola. But as Henry Ridgwell reports from London, the song has not been universally welcomed in Africa - where local music stars have recorded their own Ebola single.

http://www.voanews.com/media/video/african-stars-give-band-aid-thirty-ebola-track-cool-welcome/2538714.html

CNN -- By Laura Smith-Spark                              Nov. 27, 2014

The first human trial of an experimental Ebola vaccine has produced promising results, U.S. scientists said, raising hopes that protection from the deadly disease may be on the horizon.

All 20 healthy adults who received the vaccine in a trial run by researchers from the National Institutes of Health in Maryland produced an immune response and developed anti-Ebola antibodies, the NIH said Wednesday.

None suffered serious side effects, although two people developed a brief fever within a day of vaccination.

The vaccine is being developed by the NIH's National Institute of Allergy and Infectious Diseases and British pharmaceutical giant GlaxoSmithKline. The process has been fast-tracked in light of the current catastrophic Ebola outbreak in West Africa, which has claimed more than 5,000 lives.

http://www.cnn.com/2014/11/27/health/ebola-outbreak/

REUTERS      By Kate Kelland                                                                                                  Nov. 26, 2014

LONDON --West Africa's Ebola epidemic could worsen further before abating but new infections should start to decline in all affected countries by the end of this year, a leading specialist on the disease said on Wednesday.

Peter Piot, one of the scientists who first identified the Ebola virus almost 40 years ago, said the outbreak was far from over, but said that "thanks to now massive efforts at all levels" what had been an exponential growth in numbers should soon begin to recede.

The death toll in the worst Ebola epidemic on record has risen to 5,459 out of 15,351 cases identified in eight countries by November 18, latest data from the World Health Organization (WHO) showed. Almost all those cases are in Guinea, Sierra Leone and Liberia.

"By the end of the year we should start seeing a real decline everywhere," Piot, who is now director of the London School of Hygiene and Tropical Medicine, told a meeting of public health experts, non-governmental organizations and officials.

http://www.reuters.com/article/2014/11/26/us-health-ebola-piot-idUSKCN0JA1AQ20141126

NATIONAL PUBLIC RADIO   By Kelly Mcevers                                                  Nov. 25, 2014
There's a new phase of Ebola in Liberia. Epidemiologists call it pingponging.

Back in March, the disease was found in the rural areas. Then as people came to the capital to seek care, it started growing exponentially there. Now, some sick people are going back to their villages, and the disease has pingponged to the rural areas again.

Read complete story and hear broadcast

http://www.npr.org/blogs/goatsandsoda/2014/11/25/366381386/as-ebola-ping-pongs-in-liberia-cases-disappear-into-the-jungle

SCIENCE        By Jon Cohen                                                                                         Nov. 21, 2014

...Just a handful of basic interventions to fight the killer effects of Ebola, including dehydration and secondary infections, could dramatically lower the CFR there, says Michael Callahan, an infectious disease specialist at Massachusetts General Hospital in Boston..

With so much room for improvement in supportive care, the current international focus on drugs is “misguided,” says Callahan, who has recently worked in Monrovia and provided care in four previous Ebola outbreaks. “While we wait for months for forthcoming experimental therapies, many lives can be saved, certainly hundreds and possibly thousands, using inexpensive and simple therapies,” he says.

Callahan is helping an international team develop guidelines dubbed Maximum Use of Supportive Therapy (MUST), aimed at keeping more patients alive. It includes intravenous (IV) drips to replace massive fluid loss from diarrhea and vomiting, a risk factor for shock; balancing of electrolytes such as calcium or potassium, which prevents kidney and heart failure; nasogastric tubes for feeding; and testing and treatment of secondary infections such as malaria. Introducing MUST will also make it easier to study new treatments, Callahan says...

Description of efforts by the big drug companies to develop an Ebloa vaccine
THE NEW YORKER    By Vauhine Vara                        Nov. 25, 2014

"...why this race to create an Ebola vaccine among Merck, GlaxoSmithKline, and Johnson & Johnson—three of the world’s biggest drug manufacturers? For years, pharmaceutical companies didn’t invest much in vaccines, partly because they were so costly and complicated to produce: they’re often made out of live bacteria, which are notoriously difficult to work with. But, over the past several years, companies have realized that the difficulties of making vaccines could be an asset, because they can make it more difficult for generic-drug companies to create copycat versions than for prescription drugs. The vaccine market has also been growing more quickly than the prescription-drug market. The World Health Organization estimates, based on various sources, that global vaccine sales rose from five billion dollars in 2000 to twenty-four billion dollars last year...."

Read complete article
http://www.newyorker.com/business/currency/race-ebola-vaccine

PLOS CURRENT OUTBREAKS                                                                              Nov. 21, 2014
By David Fisman and Ashleigh Tuite, Dalla Lana School of Public Health, University of Toronto

As removal of population-level susceptibility through vaccination could be a highly impactful control measure for this epidemic, we sought to estimate the number of vaccine doses and timing of vaccine administration required to reduce the epidemic size. Our base model was fit using the IDEA approach, a single equation model that has been successful to date in describing Ebola growth. We projected the future course of the Ebola epidemic using this model. Vaccination was assumed to reduce the effective reproductive number. We evaluated the potential impact of vaccination on epidemic trajectory under different assumptions around timing of vaccine availability.

TIME MAGAZINE By Alexandra Sifferlin                          Nov. 25, 2014
 By  Alexandra Sifferlin                       

Scientists are scurrying to get their Ebola vaccines through the necessary safety trials before they can be used widely. That includes the University of Maryland School of Medicine, which recently kicked off the latest step in their research: figuring out the appropriate dosing for the vaccine that’s both effective and safe.

The University of Maryland is one of a handful of institutions involved in the testing of an experimental but promising vaccine developed by the National Institutes of Health’s Vaccine Research Center (VRC) and GlaxoSmithKline (GSK). The hope is that the vaccine will pass through early trials needed by end of December so that the World Health Organization (WHO) and a panel of outside experts can decide whether to move on to a large efficacy trial, which would mean vaccinating a lot of people in West Africa to see how well it works.